The development of vaccines against SARS-CoV-2 is in full swing. Nevertheless, it will take at least a year for an active ingredient to hit the market. It is unclear whether the virus is still rampant.

Only a month has passed since Chinese scientists decoded the genetic information of the SARS-CoV-2 coronavirus and made it available to the global research community. 

Numerous research-based pharmaceutical companies, universities, and other research institutions started to work immediately. In the meantime, the number of laboratories working intensively on vaccine development to combat SARS-CoV-2 has grown so much that it is difficult to keep an overview. 

In addition to the large research institutes, such as the Institute for the Control and Prevention of Viral Diseases in Mainland China, researchers in Hong Kong, the USA, Germany, France, Australia, Canada, and Israel are eager to help. 

Several projects are funded by CEPI, an international partnership to fight epidemics funded by government and private funding. 

CEPI is currently promoting vaccine developments from CureVac (Germany), Inovio and Moderna (both USA). There is also a project by the University of Queensland (Australia), which has been testing an animal-model vaccine since the end of February. 

The CEPI projects are also supported by the US companies Dynavax and Glaxo Smith Kline (GSK), which are responsible for the development of adjuvants. These are potentiators that ensure that fewer antibodies per vaccine dose are sufficient to trigger an immune response.

In addition to the CEPI projects, Johnson & Johnson,   Novavax (both USA), Sanofi (France and multinational) and the Canadian VIDO-InterVAC have also announced their own vaccine developments.

Closely interlinked with university research 

International efforts include universities in Marburg (Germany), Hong Kong, Saskatchewan (Canada), Cambridge (UK) and institutes in Israel.


Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: